Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
5000 participants
OBSERVATIONAL
2020-03-10
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biology Studies of Hematologic Cancers
NCT00923442
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
NCT04298892
Characteristics and Outcomes of Patients With Hematological Malignancies
NCT06402175
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression
NCT04137523
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
NCT01137643
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Simultaneously a tissue microarray (TMA) of diagnostic samples is compiled using representative annotated tissue areas. This TMA is used in combination with additional control material to identify prognostic and predictive biomarkers.
A combined microarray dataset of hematological malignancies (Hemap) is utilized to point out genes of possible drug targets, disease specific markers, prognostic markers, or predictive markers.
The clinical datasets and Hemap dataset is ultimately utilized to gain knowledge, new tools for prognostication and diagnostics, and targets for treatment. Artificial intelligence -assisted differential diagnostics will be tested.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampere University
OTHER
University of Eastern Finland
OTHER
Fimlab Oy
UNKNOWN
Helsinki University Central Hospital
OTHER
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matti Vänskä
Principal Investigator, MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Artturi Mäkinen, MD
Role: PRINCIPAL_INVESTIGATOR
Tampere University
Olli Lohi, MD, PhD
Role: STUDY_CHAIR
Tampere University
Merja Heinäniemi, PhD
Role: STUDY_CHAIR
University of Eastern Finland
Matti Vänskä, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Tampere University Hospital
Tiina Lyly-Yrjänäinen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Tampere University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampere Univerisity Hospital
Tampere, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R19060B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.